Novo Nordisk has announced that a contract manufacturer filling syringes for Wegovy pens for the US market has temporarily stopped deliveries and manufacturing following issues with Good Manufacturing Practices.
As a consequence, Novo Nordisk does not expect to be able to meet demand in the US in the first half of 2022 and few new patients are expected to be able to initiate treatment. The priority for Novo Nordisk is patients who have already initiated treatment with Wegovy. Novo Nordisk currently expects to be able to meet demand in the US in the second half of 2022.
The supply challenges will not impact the previously communicated financial outlook for 2021, states the company.
Photo of Biopharm production, New Hampshire, US. Technician working in the biopharmaceutical API production.